People with glaucoma and eye doctors face a dilemma. On one hand, patients with glaucoma are at high risk of losing their eyesight if their disease progresses undetected and essential therapy adjustments are delayed. On the other hand, these typically elderly, vulnerable individuals are often hampered in seeing their doctor for office visits, particularly during a lockdown.
CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA® in gene therapy
CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of a license agreement with Biogen Inc. (Biogen; Nasdaq: BIIB) for the use of CEVEC’s proprietary ELEVECTA® Technology for the manufacturing of adeno‐associated virus (AAV) vectors for gene therapy applications.